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Abstract
Epstein-Barr virus (EBV) may cause a variety of virus-associated diseases, but no antiviral agents have yet been developed
against this virus. Animal models are thus indispensable for the pathological analysis of EBV-related infections and the
elucidation of therapeutic methods. To establish a model system for the study of EBV infection, we tested the ability of B95–
8 virus and recombinant EBV expressing enhanced green fluorescent protein (EGFP) to replicate in human lymphoid tissue.
Human tonsil tissues that had been surgically removed during routine tonsillectomy were sectioned into small blocks and
placed on top of collagen sponge gels in culture medium at the air-interface, then a cell-free viral suspension was directly
applied to the top of each tissue block. Increasing levels of EBV DNA in culture medium were observed after 12–15 days
through 24 days post-infection in tissue models infected with B95–8 and EGFP-EBV. Expression levels of eight EBV-
associated genes in cells collected from culture medium were increased during culture. EBV-encoded small RNA-positive
cells were detected in the interfollicular areas in paraffin-embedded sections. Flow cytometric analyses revealed that most
EGFP
+ cells were CD3
2 CD56
2 CD19
+ HLA-DR
+, and represented both naı ¨ve (immunoglobulin D
+) and memory (CD27
+)B
cells. Moreover, EBV replication in this model was suppressed by acyclovir treatment in a dose-dependent manner. These
data suggest that this model has potential for use in the pathological analysis of local tissues at the time of primary
infection, as well as for screening novel antiviral agents.
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Introduction
Epstein-Barr Virus (EBV) is a universal human c-herpesvirus,
generally transmitted via saliva, with the oropharynx as the site of
infection [1,2]. Primary EBV infection occurs most frequently in
infancy and childhood, and in many cases causes either no or only
nonspecific symptoms. In cases of primary infection among
adolescents and young adults, infectious mononucleosis (IM) often
develops, and the course may sometimes be severe or fatal. After
infection, EBV remains in most adults as an asymptomatic latent
infection, but may cause neoplastic disorders such as Burkitt’s
lymphoma or post-transplant lymphoproliferative disorder
(PTLD).
Although EBV may cause a variety of disorders, no vaccine or
antiviral agent has yet been developed against this virus [1,2]. In
general, animal models are indispensable for the pathological
analysis of viral infections and the elucidation of methods of
treatment and prevention, but EBV only infects humans in nature
and limited animal species under experimental conditions. Various
infection models have been used to investigate EBV-associated
diseases [3,4,5,6,7]. Mouse models that partially reconstitute
human immune system components after engagement of hema-
topoietic progenitor cells are of particular interest, because they
reproduce human immunity and diseases caused by EBV. Several
mouse models of immunodeficiency have been applied, including
Rag2
2/2 cc
2/2 mice [8,9], NOD/SCID mice [10], NOD/
SCID/cc
2/2 mice [11,12,13], BLT mice (NOD/SCID mice with
implantation of human fetal liver and thymus pieces under the
renal capsule) [14], and NOD/Shi-SCID/IL-2Rc
null (NOG) mice
[15]. Of these, the NOG mice model [15] has been used to show
that B-cell lymphoproliferative disorder arises during EBV
infection with a high viral load, whereas asymptomatic persistent
infection arises from infection with a low viral load. In addition,
EBV-specific T-cell responses and EBV-specific antibodies were
detected in blood, revealing this mouse model as a useful tool for
investigating the pathogenesis, prevention, and treatment of EBV
infection. Culture models using human lymphatic tissues, however,
appear advantageous for the study of localized pathology in EBV
infection. We therefore focused on a model of infection using
human tonsillar lymphoid tissues.
Numerous reports have described the use of viral infection
models using human tonsillar lymphoid tissues for the study of
human immunodeficiency virus (HIV) [16], while others have
described the use of such models for investigating other members
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25490of the herpesvirus family, such as human herpesvirus (HHV)-6,
HHV-7, and herpes simplex virus (HSV)-2 [17,18,19]. The
palatine tonsils comprise typical lymphoid tissue and are also the
natural portal of entry for EBV, thus showing great potential for
reproducing the pathology of primary infection with EBV. The
present study used human tonsillar lymphoid tissues to establish an
EBV infection model and investigated infected cells during the
initial stage of infection. We also tested the utility of this model as a
screening system for antiviral agents.
Materials and Methods
Ethics statement
Human subject protocols were approved by the institutional
review board of Nagoya University School of Medicine (2006-
450). Written informed consent was provided by study participants
and/or their legal guardians prior to enrolment.
Virus stocks
Cell-free virus solution was obtained from culture supernatant
of B95–8 cells (an EBV-infected marmoset cell line) (ATCC) after
centrifuging for 5 min at 3,0006g and filtration through a 0.45-mm
membrane filter. In some experiments, we also used supernatants
containing recombinant EBV expressing enhanced green fluores-
cent protein (EGFP), in which a gene cassette consisting of the
EGFP gene driven by the simian virus 40 promoter and a
neomycin resistance gene driven by the simian virus 40 promoter
were inserted into the viral BXLF1 gene [20]. Titers of virus in the
50% transforming dose (TD50) were determined using the Reed-
Muench method, as described elsewhere [15,21]. Calculated titers
were 1610
2 TD50/ml for B95 and 1610
3 TD50/ml for EGFP-
EBV.
Tissue culture and viral infection
Human tonsils surgically removed during routine tonsillectomy
and not required for clinical purposes were received within
several hours of excision, then dissected, cultured, and infected, as
described elsewhere [16,22,23]. Since EBV-specific immune
responses may impact cellular infection, we only used tonsils
from EBV-seronegative individuals. Serological tests for anti-EBV
antibodies were examined 2–4 weeks preoperatively and negative
results for viral capsid antigen immunoglobulin (Ig) G and EBV
nuclear antigen were confirmed. In brief, the tonsils were washed
thoroughly with medium containing antibiotics, sectioned into
cubes with an average weight of 5 mg, and placed on top of
collagen sponge gels in culture medium at the air-interface. For
EBV infection, 10 mL of clarified viral suspension was directly
applied on top of each tissue block. The culture medium used to
bathe 54 tissue blocks in six wells was collected every 3 days after
viral inoculation. Cell-free supernatants and cells were obtained
after centrifugation of collected medium and used for the
following assays. Cells collected from culture medium were
considered to have come from infected tissues. Most of the
epithelial tonsillar layers were lost during preparation of tissue
blocks, so replication of EBV in epithelial cells could not be
examined.
Quantification of EBV DNA
Viral DNA was extracted from either 200 mL of cell-free
culture supernatants or from 5610
5 cells collected from culture
medium using QIAamp DNA blood kits (Qiagen). Real-time
quantitative PCR assays were performed as previously described
[24,25,26].
RNA purification and real-time RT-PCR
RNA was extracted from 5610
5 cells from culture medium with
a QIAmp RNeasy Mini Kit (Qiagen). Viral mRNA expression was
quantified by one-step multiplex real-time reverse transcription
(RT)-PCR using the Mx3000P real-time PCR system (Stratagene),
as described previously [27,28], to examine expression levels of
two lytic genes (BZLF1 and gp350/220) and six latent genes (EBV-
encoded nuclear antigen (EBNA)1, EBNA2, latent membrane
protein (LMP)1, LMP2, EBV-encoded small RNA (EBER)1, and
BamHI-A rightward transcripts (BARTs)). The stably expressed
housekeeping gene b2-microglobulin (b2M) was used as an
endogenous control and reference gene for relative quantification.
Each experiment was conducted in triplicate and results are shown
as the mean of three samples with standard errors.
Immunohistology and in situ hybridization
Tissue blocks were fixed with 10% buffered formalin,
embedded in paraffin, and sectioned at 5 mm and stained with
hematoxylin and eosin (HE). The monoclonal antibodies used
were anti-CD3, anti-CD20, anti-follicular dendritic cell (FDC),
EBNA2, LMP1 and BZFL1 (Dako), all of which were used after
antigen retrieval following heating in a microwave oven [27,29].
In situ hybridization was performed using the EBER1 probe
(Dako) as previously described [24,27]. Hybridization was
detected using mouse monoclonal anti-fluorescein isothiocyanate
(Dako) and a Vectastain ABC kit (Vector). For both immuno-
staining and in situ hybridization, diaminobenzidine was used for
visualization.
Flow cytometry
At day 15–24 post-infection with EGFP-EBV, single-cell
suspensions were dissected from tissue blocks by mechanical
dissociation. Tissue blocks were placed into a petri plate with
complete medium and gently ground with pestles. As shown
previously, this procedure releases lymphocytes from stromal
elements [23]. Similarly, cells that had emigrated into the collagen
sponge were mechanically squeezed out and collected by
centrifugation. Cell debris and fragments were removed and
mononuclear cells (MNCs) were purified by Ficoll-Hypaque
centrifugation [30]. MNCs were washed three times and stained
using a combination of the following monoclonal antibodies
(mAbs): phycoerythrin (PE)-labeled anti-CD19 (clone HD37;
Dako); anti-CD3 (clone UCHT1; eBioscience); anti-CD56 (clone
IM2073; Beckman Coulter); PE-cyanin 5 (PC5)-labeled anti-CD56
(clone IM2654; Beckman Coulter); and anti-HLA-DR (clone
IMMU357; Beckman Coulter). In a few experiments, collected
cells were also stained with 7-amino-actinomycinD (7-AAD; BD
Pharmingen) at day 24, to exclude dead cells on samples.
Discrimination between infection with memory or naive B cells
was determined using the following antibody combination: PE-
labeled anti-CD27 (clone M-T271; Becton Dickinson); anti-IgD
(clone IgD26; Miltenyi Biotec); and PC5-labeled anti-CD19 (clone
HIB19; eBioscience). Isotype-matched monoclonal mouse IgG
antibodies were used in each experiment as controls. Stained cells
were analyzed using FACSCalibur and CellQuest version 5.2.1
software (Becton Dickinson).
Acyclovir (ACV) treatment
To test the anti-EBV activity of ACV (GlaxoSmithKline), B95-
infected tissue blocks were incubated with culture medium
containing ACV at various concentrations (1.5, 5, 15 or 45 mg/
ml). Culture medium was changed every 3 days after viral
inoculation, and ACV was added with every medium change. A
Primary EBV Infection in Human Tonsil Explant
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25490sample of medium collected from each exchange was used for
quantification of EBV DNA, as previously mentioned.
Flow cytometric in situ hybridization (FISH) assay
To quantify EBV-infected cells and to analyze the cell types
of EBV-infected populations, FISH assays were used [31].
Briefly, 5610
5 MNCs were stained with phycoerythrin cyanine
5 (PC5)-labeled anti-CD45 (clone HI30; Biolegend) monoclonal
antibodies for 1 h at 4uC. Isotype-matched monoclonal mouse
IgG antibodies were used as controls. After staining with
antibodies, cells were fixed with 1% acetic acid/4% parafor-
maldehyde, permeabilized with 0.5% Tween 20/phosphate-
buffered saline, and hybridized with a fluorescein-labeled
EBER-specific peptide nucleic acid probe (Y5200; Dako).
Fluorescence intensity was enhanced using the AlexaFluor 488
Signal Amplification Kit (Molecular Probes), and stained cells
were analyzed using FACSCalibur and CellQuest software (BD
Biosciences).
Statistical analyses
Data are presented as means 6 standard error of the mean.
Statistical analyses were conducted using StatView version 5.0
Figure 1. Kinetics of EBV DNA and expression patterns of EBV-related genes in human tonsil tissue explants infected with B95–8.
Culture medium was changed every 3 days, and collected medium was centrifuged. Cell-free supernatants and cells collected from culture medium
were used for quantification of EBV DNA by real-time PCR assay and quantification of viral mRNA by real-time RT-PCR assay. Data are presented as
mean 6 standard error of the mean. A) Tissue blocks on top of collagen sponge gels in a six-well plate. B) Kinetics of EBV DNA in cell-free
supernatants. Average data were obtained from tissues derived from 12 donors. C) Plots of accumulated EBV DNA in cell-free culture medium after
day 12 post-infection (n=12). D) Kinetics of EBV DNA in cells from medium (n=12). E) Levels of EBV-related gene expressions in cells at 3, 12, and 24
days post-infection (n=4).
doi:10.1371/journal.pone.0025490.g001
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compare inhibition rates of EBV infection at each concentration
of ACV. Values of P,0.05 were considered statistically
significant.
Results
Replication of EBV B95–8 in human tonsil tissue explants
To establish a model system for the study of EBV infection, we
tested the ability of B95–8 virus to replicate in human tonsillar
tissue. The prepared tonsil tissue blocks (Fig. 1A)w e r ee x p o s e d
to B95–8, and cell-free supernatants and cells were collected.
Figure 1B shows the kinetics of EBV DNA in culture
supernatants of infected tissues at each time point. EBV DNA
level gradually dropped and was minimal on day 12 post-
infection, then steadily increased. When we applied the viral
suspension on top of collagen sponge gels without tonsil tissues
and changed the culture medium every 3 days, EBV DNA in
culture medium gradually decreased and fell below the limit of
detection by day 12 post-infection (data not shown). Kinetics
before day 12 post-infection resemble those in EBV-infected
tissue before day 12 post-infection, suggesting that EBV
replication may become apparent after day 12 post-infection.
We therefore showed the kinetics of EBV DNA in culture
medium as a cumulative curve by totaling values from day 12
post-infection and after (Fig. 1C). Levels of viral DNA peaked
between 1.3610
5 and 4.3610
7 (median, 4.1610
6) genome-
equivalents/ml of culture supernatant on day 24 post-infection
(n=12). Increasing levels of EBV over time were also observed in
cells from culture medium with peak levels between 1.2610
4 and
6.7610
6 (median, 8.0610
5) genome-equivalents/mgo fD N Aa t
day 24 post-infection (n=12) (Fig. 1D).
Next, we analyzed expressions of eight EBV-associated genes
in cells from culture medium using a real-time RT-PCR assay
(Fig. 1E). Expression levels of all genes examined increased
after day 12 post-infection (n= 4 ) .T h ei m m e d i a t ee a r l yg e n e
BZLF1 was not detected on day 3 post-infection, but was
detected after day 12 post-infection. In some series of
experiments, we used RNA extracted from cells from dissected
tissues and measured EBV gene expression. Expression patterns
Figure 2. Kinetics of EBV DNA and expression patterns of EBV-related genes in human tonsil tissue explants infected with EGFP-
EBV. Cell-free supernatants and cells collected from culture medium were used for quantification of EBV DNA by real-time PCR assay and
quantification of viral mRNA by real-time RT-PCR assay. Data are presented as mean 6 standard error of the mean. A) Plots of accumulated EBV DNA
in cell-free culture medium after 12 days post-infection (n=8). B) Plots of accumulated EBV DNA in cells from medium (n=2). C) Levels of EBV-related
genes expressions in cells at 3 and 24 days post-infection (n=3).
doi:10.1371/journal.pone.0025490.g002
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blocks (data not shown).
Replication of recombinant EGFP-EBV in human tonsil
tissue explants
We tested the ability of EGFP-EBV to replicate in human tonsil
tissues in the same way as B95–8. Levels of EBV DNA in culture
supernatants of EGFP-EBV-infected tissues as primary data were
measured for each time point. EBV DNA levels gradually
decreased and were minimal on days 12–15 post-infection, then
steadily increased (data not shown). Productive infection was
documented by the kinetics of EBV DNA accumulation in culture
supernatants of infected tissues using real-time quantitative PCR
(Fig. 2A), with peak levels between 2.1610
4 and 2.5610
6
genome-equivalents/ml of culture supernatant (median, 3.5610
5
genome-equivalents/ml of culture supernatant) at day 24 post-
infection in tissues infected with EGFP-EBV (n=8). Increasing
levels of EBV over time were also detected by measuring cell-
associated DNA (Fig. 2B), with peak levels between 1.4610
5 and
4.1610
5 genome-equivalents/mg DNA at day 24 post-infection
(n=2).
Expressions of viral genes in cells collected from culture medium
of EGFP-EBV infected tissues are shown in Figure 2C.
Expressions of lytic cycle genes and increased levels of genes
expression were subsequently observed at day 24 post-infection
(n=3). Use of recombinant EGFP-EBV did not influence EBV
gene expression compared to that in B95–8.
Histological analyses in EBV-infected human tonsil tissues
Histological analysis showed that tissues retained their gross
morphology, even at day 24 post-infection (Fig. 3A, n=4).
Immunohistochemical analysis performed by staining paraffin-
embedded sections of tissue blocks with anti-CD3, anti-CD20, and
anti-FDC mAbs revealed the presence of T cells (Fig. 3B), B cells
(Fig. 3C), and FDCs (Fig. 3D). B cells were concentrated in
follicular areas (Fig. 3C), while T cells (Fig. 3B) were confined to
interfollicular areas. FDCs were detected in follicular areas
(Fig. 3D). EBER-positive cells were detected, mainly in the
interfollicular areas (Fig. 3E). EBER-positive cells represented a
mixture of cells ranging from large lymphoid blasts to small
lymphoid cells (Fig. 3F). No morphological evidence suggested
EBV infection of cells other than lymphoid cells. BZLF1, a
hallmark of lytic infection, was also detected in lymphoid cells
(Fig. 3G), while EBNA2 and LMP1 were not detected in tissue
samples.
Target cells of primary EBV infection in human tonsil
tissues
To quantify and identify EBV-infected cells in tonsil tissues, we
investigated the lineage of EGFP
+ cells prepared from tissue blocks
infected with EGFP-EBV by flow cytometry using mAbs directed
against several lymphocyte membrane antigens. GFP signals were not
clearly detected before day 15, and the initial EBV-infected cells could
not be determined (data not shown). Collected cells were stained with
7-AAD at day 24 in three experiments and 7-AAD-positive cells
comprised 2.361.6% of the lymphocyte population gated by standard
forward and side scatter profiles (data not shown). Figure 4A shows a
representative experiment with results (n=4) indicating that the
majority of EGFP
+ cells were CD19
+ cells, with a very limited
proportion of other types of lymphocytes. Figure 4B represents the
kinetics in the proportion of EGFP
+ CD19
+ cells among all CD19
+
cells at 15–24 days post-infection (n=4). Mean proportions of EGFP
+
CD19
+ cells increased over time, with frequencies of 3.761.3%,
22.569.1%, 25.766.2%, and 40.8611.3% at days 15, 18, 21, and 24
day post-infection, respectively. These data indicate that EBV mainly
infected B cells in tonsillar tissue explants. Furthermore, EGFP
+ cells
were closely examined to determine the phenotype of EBV-infected
cells.A representative result isshowninFigure5(n=2).MostEGFP
+
cells were CD3
2 CD56
2 CD19
+ HLA-DR
+, and both naı ¨ve
(CD19
+IgD
+, mean 22.666.0% of EGFP
+ cells) and memory
(CD19
+ CD27
+, mean 73.567.5% of EGFP
+ cells) B cells were
detected.
Inhibition of EBV replication by ACV in human tonsil
tissues
Finally, we investigated the anti-EBV activity of ACV in
infected tonsil tissues. Blocks of tonsil tissues were cultured with
medium containing various concentrations of ACV. The amount
Figure 3. Histological analyses of tonsil tissues infected with
B95–8 using immunostaining and in situ hybridization with
EBER-RNA. Samples were obtained from EBV-infected tissues at 24
days post-infection. Pictures are representative of results from four
experiments. A) Low-power view of tonsillar lymphoid tissue (HE stain).
Magnification, 6100. B) Low-power view of CD3
+ lymphocytes in an
interfollicular area (CD3 stain). Magnification,6100. C) Low-power view
of CD20
+ lymphocytes in a follicular area (CD20 stain). Magnification,
6100. D) High-power view of anti-follicular dendritic cell (FDC)
+ in a
follicular area (anti-FDC stain). Magnification, 6400. E) Low-power view
of EBER
+ lymphocytes (EBER ISH stain). Magnification, 6100. F) High-
power view of EBER
+ lymphocytes in an interfollicular area (EBER ISH
stain). Magnification,6400. G) High-power view of BZLF1
+ lymphocytes
(arrows) in an interfollicular area (BZLF1 stain). Magnification, 6400.
doi:10.1371/journal.pone.0025490.g003
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cells collected from culture medium. EBV replication was
suppressed by ACV treatment in a dose-dependent manner
(Fig. 6A). Mean accumulations of EBV DNA in culture medium
at day 24 post-infection were 1.960.9610
5, 5.763.1610
5,
5.462.6610
5, 9.965.3610
5, and 2.661.4610
6 genome-equiva-
lents/ml in tissues treated with 45, 15, 5, 1.5, and 0 mg/ml of
ACV, respectively (n=3). Reduction rates in total production of
EBV DNA accumulated in culture medium at day 24 post-
infection were 9064%, 7667%, 7763%, and 6462% in tissues
treated with 45, 15, 5, and 1.5 mg/ml of ACV (P,0.01),
respectively. Suppression of EBV replication was also documented
by measurement of EBV DNA in cells from culture medium
(Fig. 6B). Mean levels of EBV DNA in these MNCs were
4.763.1610
4, 8.765.2610
4, 2.561.8610
4, 2.761.8610
5, and
6.963.9610
5 genome-equivalents/mg DNA at day 24 post-
Figure 4. Phenotype of EGFP
+ cells in human tonsil tissue infected with EGFP-EBV. At 15–24 days post-infection, single cell suspensions
were dissected from tissue blocks. Cells were stained with phycoerythrin (PE)-labeled anti-CD19, CD3, CD56 monoclonal antibodies, then analyzed by
flow cytometry. A) A representative experiment is shown (n=4). Density plots represent CD19, CD3, CD56 versus EGFP for control and EGFP-EBV-
infected tissues at 24 days post-infection. Numbers in quadrants indicate percentages of lymphocytes for each surface immunophenotype. B) Mean
proportion of EGFP
+ CD19
+ cells among CD19
+ cells at 15–24 days post-infection. Average data were obtained from 27 blocks of tissue derived from
four donors. Results represent mean 6 standard error of the mean. ctrl, control (uninfected tonsil tissues).
doi:10.1371/journal.pone.0025490.g004
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ACV, respectively (n=3). Moreover, the number of EBV-infected
cells was compared in the presence or absence of ACV using FISH
assay. The percentage of EBER
+ cells among CD45
+ cells was
decreased at day 24 post-infection in a dose-dependent manner
(10% with 45 mg/ml of ACV, 19% with 15 mg/ml, 24% with
5 mg/ml, and 32% without ACV, n=1) (Fig. 6C).
Discussion
Viral infection models using human lymphoid tissues have the
advantages of enabling culturing while maintaining tissue
cytoarchitecture (including major lymphocyte subtypes and the
follicular-dendritic cell network) and supporting productive virus
infection without exogenous activation and stimulation. These
models have been reported as useful for analyzing the pathoge-
nicity of viruses that mainly infect lymphoid tissues [16]. In a study
of the herpesvirus family, Grivel et al. used a tonsillar infection
model to investigate cellular tropism and the pathogenic effects of
HHV-6, demonstrating that HHV-6 infects efficiently without
exogenous stimulation and that T-lymphocytes are the main cells
infected [19]. The present study established an experimental EBV
infection model with a culture system using tonsil tissues and
confirmed that the amount of EBV-DNA in medium and in cells
Figure 5. Phenotype of EGFP
+ cells in human tonsil tissue infected with EGFP-EBV using flow cytometry. Samples were obtained from
EBV-infected tissues at 24 days post-infection. EGFP
+ (red) and EGFP
2 (grey) MNCs were gated and plotted on quadrants as PE-labeled and PC5-
labeled surface antigens. A representative experiment is shown (n=2). Numbers in quadrants indicate percentages of EGFP
+ lymphocytes for each
surface immunophenotype.
doi:10.1371/journal.pone.0025490.g005
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was pronounced from $12 days post-infection, with the amount of
virus starting to increase later using EBV than in tonsillar infection
models using HHV-6 or HHV-7 [18,19]. This was not regarded as
a problem with the tonsillar infection model, but rather as
resulting from differences in viral proliferation; however, estab-
lishment of an EBV infection model may be more difficult for this
reason. Yajima et al. infected humanized NOG mice intravenously
with EBV and reported that EBV-DNA in blood increased after
3–4 weeks [15]. Changes in the amount of DNA in our infection
model were not inconsistent with those results. We also
investigated expression of EBV-related genes in cells obtained
from our infection model, revealing expression of lytic genes and
increased levels of gene transcripts over time, in addition to latent
genes expressed as latency type III. These data show that EBV
produces both latent and productive infections in a tonsillar
infection model. Several histological studies of IM tonsils have
shown the presence of B cells expressing latency types III, II, and I,
as well as lytic genes [32,33]. In the present EBV-infection model,
EBV de novo synthesis was not shown directly. However, several
results suggested that at least some of the infected cells in this
model gave rise to progeny virus: (1) the amount of EBV DNA in
both culture media and cells markedly increased after day 12 post-
infection, (2) immediate early gene BZLF1 was detected in
lymphoid cells both in the immunohistochemical analysis and in
the quantification of mRNA expression, and (3) ACV treatment
reduced the levels of EBV DNA. This model may represent early
events in primary EBV infection, before the emergence of IM
symptoms, rather than a stable latent infection. Taken together,
the tonsillar infection model is useful for analyzing the pathology
of primary infection with EBV.
EBV is believed to be transmitted orally at oropharyngeal sites
[34]. For this reason, numerous histological studies of IM tonsils
have examined viral-cell interactions during primary infection
[32,35,36]. These investigations have been unable to detect EBV
infection of the tonsillar epithelium, with most reports stating that
the main infected cells are B cells [32,35,36,37]. Our histological
analysis also suggested B-cell infection. Flow cytometric analysis
also showed that B cells were mainly infected, supporting the
findings of previous studies. The events involved in virus
colonization of the B-cell system during primary infection remain
poorly understood. Various studies have looked at tonsillar EBV-
infected B-cell subsets in healthy virus carriers [38,39,40]. Joseph
et al. used IgD mAb from the tonsils of healthy virus carriers to sort
each B-cell subset and performed limiting-dilution DNA PCR on
each subset, detecting EBV in both naı ¨ve (IgD
+) and memory B
cells [38].
Meanwhile, the only report on EBV-infected B-cell subsets in
tonsils obtained from patients with IM has been the recent study
by Chaganti et al. [36]. They sorted each B-cell subset using CD27,
IgD, and CD38 mAbs from tonsils they obtained and performed
quantitative PCR on each subset, reporting that the amount of
DNA was greatest in CD38
+ cells, followed by memory cells
(CD27
+) and finally naı ¨ve (IgD
+ CD27
2) B cells. We investigated
the lineage of EGFP
+ cells dissected from tissue blocks infected
with EGFP-EBV by flow cytometry using mAbs directed against
several lymphocyte membrane antigens and the proportion of
EBV-infected B cells was higher among memory cells (CD27
+)
than among naı ¨ve cells (IgD
+), consistent with findings from the
above study. This showed that the tonsillar infection model is
useful for analyzing EBV-infected lymphocyte subsets. Further
observation of changes in subsets over time as well as of additional
surface or intracellular molecules, such as cell adhesion markers
Figure 6. Inhibition by acyclovir (ACV) of EBV replication in
human tonsillar tissues explants. Human tonsillar tissues were
infected with B95–8 and treated with ACV at various concentrations.
Antiviral activity of ACV was evaluated by comparing viral replication in
ACV-treated tissues with that in untreated donor-matched control
tissues. Data are presented as means 6 standard errors of mean. A)
Kinetics of EBV replication were measured by real-time PCR assay for
viral DNA in culture medium (n=3). B) EBV DNA was quantified in cells
at 24 days post-infection (n=3). C) Comparison of the number of EBV-
infected cells in the presence or absence of ACV at 24 days post-
infection using FISH assay (n=1).
doi:10.1371/journal.pone.0025490.g006
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examine the function of EBV-infected cells.
Conversely, tissue culture models show a number of limitations.
The first is that wide differences in proliferative capacity within
tissue exist between donors. In practice, even when experiments
have been performed under the same protocol, differences of
around 100-fold have occurred in amounts of DNA between
tissues. The same phenomenon has also been observed in tonsillar
infection models using other viruses [19,41]. This is probably
because the structure and cell composition of tonsil tissue vary
greatly among donors. The second limitation that can be raised is
that tissues deteriorate as a result of long-term culture. We
cultured cells for 4 weeks, but regarded culture for longer than this
period as difficult due to deteriorations observed in tissue samples.
Histological investigation of tissue segments also showed that
although the structures were maintained, the number of
lymphocytes decreased significantly. The third limitation is that
investigation of EBV-specific immune responses was difficult in
this model. Symptoms of IM are believed to be closely related to
the specific immune responses of the host to EBV infection [1].
With respect to specific immune response in tonsillar infection
models, antibody response to antigen load with antigens such as
diphtheria and tetanus toxoids has been reported [42]. However,
IM symptoms appear as late as 4–6 weeks after viral transmission
in vivo [2]. Since tissue deterioration makes culture for longer
periods than this difficult, evaluation of specific immune responses
was considered difficult.
Treatment of IM and PTLD with regular antiviral agents is not
recommended [1], but antiviral agents may be required in cases
such as immunocompromised patients with severe IM or HIV-
infected patients with oral hairy leukoplakia, and novel antiviral
agents need to be developed for treatment in such cases. ACV is
known to be a guanosine nucleoside analog with activity against
several types of a-herpesvirus. ACV inhibits virus-associated DNA
polymerase, suppressing virus replication. Although some reports
have indicated that ACV is effective against EBV in vitro [43,44],
clear efficacy in actual clinical practice has not been established
[1,2]. Using the tonsillar infection model, we showed that ACV
exerts a dose-dependent antiviral action. For previous evaluations
of in vitro efficacy, EBV-infected cell suspension cultures have been
used [43,44]. Actual EBV infection, however, occurs in the
oropharyngeal lymphoid tissues [2,34], so use of a tonsillar
infection model may more closely reproduce the in vivo
environment. The tonsillar infection model was also regarded as
applicable to the screening of novel antiviral agents.
In this study, we established an EBV infection model using
human tonsil tissues. EBV infection and proliferation in this model
could be observed without the need for any special exogenous
stimulation. Use of flow cytometry also enabled qualitative and
quantitative analysis of infected cells. This model has potential for
use in the pathological analysis of local tissues at the time of
primary infection, as well as for screening novel antiviral agents.
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